Literature DB >> 11576791

Evaluation of E test, disk diffusion and broth microdilution to establish tentative quality control limits and review susceptibility breakpoints for two aerobic actinomycetes.

P Tomlin1, C Sand, R P Rennie.   

Abstract

A single laboratory study was carried out to compare E Test with broth microdilution and disk diffusion to establish tentative quality control ranges for Nocardia asteroides ATCC 19247 and Rhodococcus equi ATCC 6939 against a panel of eight antimicrobial agents. Reproducibility testing was performed on 12 consecutive days to establish tentative quality control ranges. A total of 36 clinical strains of the Nocardia asteroides complex and 5 Rhodococcus strains were used in the study. Both candidate control strains and clinical strains grew well on cation-adjusted Mueller-Hinton agar. Adequate growth occurred at 48 to 72 h for the Nocardia isolates and 24 to 48 h for Rhodococcus. A standardized primary inoculum of 5 x 10(4) CFU/mL was used for performance of E Test and disk diffusion for the Nocardia isolates. Tentative population-based error rates were calculated using current breakpoints for Enterobacteriaceae for E Test compared with disk diffusion for the 36 clinical strains of Nocardia species. Significant very major error rates were observed for imipenem (22%) and minor error rates varied from 2.7% to 50%. These methods require more extensive validation before definitive breakpoint criteria can be established.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11576791     DOI: 10.1016/s0732-8893(01)00273-5

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  7 in total

1.  Comparison of Etest, disk diffusion, and broth macrodilution for in vitro susceptibility testing of Rhodococcus equi.

Authors:  Londa J Berghaus; Steeve Giguère; Kristen Guldbech; Eleanor Warner; Ukachi Ugorji; Roy D Berghaus
Journal:  J Clin Microbiol       Date:  2014-11-05       Impact factor: 5.948

2.  Antimicrobial susceptibility among clinical Nocardia species identified by multilocus sequence analysis.

Authors:  Lisa R McTaggart; Jennifer Doucet; Maria Witkowska; Susan E Richardson
Journal:  Antimicrob Agents Chemother       Date:  2014-10-27       Impact factor: 5.191

3.  In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods.

Authors:  Emilia Cercenado; Mercedes Marín; Mónica Sánchez-Martínez; Oscar Cuevas; José Martínez-Alarcón; Emilio Bouza
Journal:  Antimicrob Agents Chemother       Date:  2006-12-28       Impact factor: 5.191

4.  Antimicrobial susceptibility testing and profiling of Nocardia species and other aerobic actinomycetes from South Africa: comparative evaluation of broth microdilution versus the Etest.

Authors:  Warren Lowman; Naseema Aithma
Journal:  J Clin Microbiol       Date:  2010-10-27       Impact factor: 5.948

5.  In vitro activity of fluoroquinolones against clinical isolates of Nocardia identified by partial 16S rRNA sequencing.

Authors:  G Hansen; S Swanzy; R Gupta; B Cookson; A P Limaye
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-11-09       Impact factor: 3.267

6.  Williamsia muralis pulmonary infection.

Authors:  Maria del Mar Tomas; Rita Moure; Juan Antonio Saez Nieto; Salvador Fojon; Ana Fernandez; Maria Diaz; Rosa Villanueva; German Bou
Journal:  Emerg Infect Dis       Date:  2005-08       Impact factor: 6.883

7.  Central venous catheter-associated Nocardia bacteremia in cancer patients.

Authors:  Fadi Al Akhrass; Ray Hachem; Jamal A Mohamed; Jeffrey Tarrand; Dimitrios P Kontoyiannis; Jyotsna Chandra; Mahmoud Ghannoum; Souha Haydoura; Ann Marie Chaftari; Issam Raad
Journal:  Emerg Infect Dis       Date:  2011-09       Impact factor: 6.883

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.